The closing price of Revance Therapeutics Inc (NASDAQ: RVNC) was $6.34 for the day, down -2.46% from the previous closing price of $6.50. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 2241288 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of RVNC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.80.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $16 previously.
On January 09, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $30 to $8.
Exane BNP Paribas Upgraded its Underperform to Neutral on August 16, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 06 ’23 when Moxie Dwight sold 11,000 shares for $17.06 per share. The transaction valued at 187,704 led to the insider holds 44,066 shares of the business.
Moxie Dwight sold 23,853 shares of RVNC for $424,920 on Sep 05 ’23. The SVP, GC & Secretary now owns 55,066 shares after completing the transaction at $17.81 per share. On Aug 03 ’23, another insider, Foley Mark J, who serves as the CEO of the company, sold 26,279 shares for $22.57 each. As a result, the insider received 593,151 and left with 840,375 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RVNC now has a Market Capitalization of 571.76M and an Enterprise Value of 796.28M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.39. Its current Enterprise Value per Revenue stands at 3.40 whereas that against EBITDA is -2.74.
Stock Price History:
Over the past 52 weeks, RVNC has reached a high of $37.98, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 6.43, while the 200-Day Moving Average is calculated to be 14.38.
Shares Statistics:
RVNC traded an average of 1.73M shares per day over the past three months and 2.86M shares per day over the past ten days. A total of 87.96M shares are outstanding, with a floating share count of 79.12M. Insiders hold about 10.31% of the company’s shares, while institutions hold 89.05% stake in the company. Shares short for RVNC as of Feb 15, 2024 were 12.34M with a Short Ratio of 7.14, compared to 14.81M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.03% and a Short% of Float of 16.00%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$1.19, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.46 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.61 and -$3.24 for the fiscal current year, implying an average EPS of -$2.24. EPS for the following year is -$1.1, with 6 analysts recommending between -$0.78 and -$1.31.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $59.6M to a low estimate of $53.47M. As of the current estimate, Revance Therapeutics Inc’s year-ago sales were $49.33M, an estimated increase of 14.40% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $67.56M, an increase of 16.20% over than the figure of $14.40% in the same quarter last year. There is a high estimate of $72.83M for the next quarter, whereas the lowest estimate is $63M.
A total of 12 analysts have provided revenue estimates for RVNC’s current fiscal year. The highest revenue estimate was $288M, while the lowest revenue estimate was $269.1M, resulting in an average revenue estimate of $281.13M. In the same quarter a year ago, actual revenue was $234.04M, up 20.10% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $378.4M in the next fiscal year. The high estimate is $406.96M and the low estimate is $339.1M. The average revenue growth estimate for next year is up 34.60% from the average revenue estimate for this year.
